Diseases /

Salivary Duct Carcinoma

Associated Genetic Biomarkers

Overview

NCI Definition: An aggressive, high grade adenocarcinoma that arises from the salivary glands. It usually affects elderly males and presents as a rapidly enlarging mass. It metastasizes to regional lymph nodes and distant anatomic sites. [1]

Clinical Trials

There
are 2 clinical trials
for salivary duct carcinoma, of which 2
are
open and 0
are
completed or closed.
Of the
trials that contain
salivary duct carcinoma as an inclusion criterion, 2 are phase 2 (2 open).

Significant Genes in Salivary Duct Carcinoma

ERBB2 is an inclusion eligibility criterion in 1 clinical
trial
for salivary duct carcinoma, of which 1
is open and 0
are closed.
Of the
trial that contains
ERBB2 status and salivary duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

References

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.